ARS Pharmaceuticals Inc. (NASDAQ: SPRY) saw its stock soar 7.34% in pre-market trading on Monday following the release of its third-quarter 2025 financial results. The biopharmaceutical company, known for its neffy® (epinephrine nasal spray) product, reported strong revenue growth that outpaced analyst expectations, despite posting a wider-than-anticipated net loss.

The company reported total revenue of $32.5 million for Q3 2025, significantly beating the analyst consensus estimate of $28.743 million. This represents a remarkable 1,470% increase from the $2.068 million reported in the same period last year. The revenue surge was primarily driven by $31.3 million in net product revenue from neffy sales in the U.S., highlighting the successful commercial launch of the company's flagship product.

However, ARS Pharmaceuticals also reported a net loss of $51.2 million, or $0.52 per share, which was wider than the analyst consensus estimate of $0.47 per share. The increased loss was largely attributed to substantial investments in marketing and commercialization efforts, with selling, general, and administrative expenses rising to $74.8 million for the quarter.

Despite the wider loss, investors appear to be focusing on the strong revenue growth and positive commercial progress of neffy. The company reported increasing healthcare provider adoption, with over 18,000 providers having prescribed neffy to date. Additionally, ARS Pharmaceuticals highlighted its expanding global presence, including recent approval in Japan and successful launches in the United Kingdom and Germany.

The company maintains a strong balance sheet with $288.2 million in cash, cash equivalents, and short-term investments as of September 30, 2025. This financial position is expected to fund operations through anticipated cash-flow break-even, providing confidence in the company's ability to continue its growth trajectory.